User switched from Finasteride to Dutasteride and oral Minoxidil after dermatologist's recommendation. Others in conversation express interest and support for the new treatment.
Hair loss journey of a 24-year-old man who tried Finasteride, RU58841, Dutasteride, and Minoxidil. Significant hairline recovery achieved after 18 months of various treatments.
Hair loss discussion includes treatments like Minoxidil, Finasteride, and RU58841. User shares 3.5-month Dutasteride experience, slightly below baseline, with thicker hairs but less density.
The user's consideration of taking finasteride as a short-term treatment, while awaiting advances in medical technology such as Pyrilutamide and GT20029; other users' experiences with Finasteride, including potential side effects.
User shared 3-year progress on Finasteride and Minoxidil for hair loss. Experienced cycles of hair worsening before improving, takes 1mg Fin daily and topical Minoxidil.
User experienced hair loss after starting dutasteride, but saw regrowth with finasteride. They wonder if dutasteride can cause initial shedding but eventually lead to hair regrowth.
A user's experience with hair loss and scalp inflammation, which was alleviated by using RU58841 along with finasteride and dutasteride. A theory of inflammation possibly being a cause of hairloss is also discussed.
A user's experience of gaining weight while taking Dutasteride, and suggestions on how to continue using it without the negative side effects, such as exercising and tracking calories or switching to Finasteride.
This post by "vicky8201" documents their progress in treating hair loss with Minoxidil and Finasteride, which resulted in a transition from NW4 to NW2.5 over the course of two months. Master_Blaster999 and lovindicks both commented on the results, noting that it is nearly impossible to grow that much hair in such a short time frame.
The experiences of users who have used RU58841 to treat hair loss, including both positive and negative effects. Some side effects reported include chest pain, joint pain in the hands, tinnitus, and increased heartbeat.
Hair loss discussion mentions treatments like Finasteride, Dutasteride, and Minoxidil. Users share experiences, side effects, and advice on using these treatments.
A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.
This user has had positive results from taking a 1 mg dose of finasteride and increasing their daily dosage of minoxidil from 2.5 to 5 mg over the course of 9 months.
Comparing the effectiveness and side effects of topical finasteride versus oral finasteride, with people sharing their experiences using both treatments to manage hair loss.
Treatments for hair loss, such as using AR receptor blockers and degraders, to see if follicles can regenerate in the long term. The conversation also discusses how hair transplants could be a potential solution.
Minoxidil increases hair count despite high prolactin being linked to hair loss. Blocking DHT is effective, but not always necessary; HMI-115 is a promising treatment for androgenetic alopecia.
OP is experiencing dandruff and is considering switching from climbazole to ketoconazole, with suggestions to use Nizoral and a routine involving ketoconazole, coconut oil, and lemon. OP is also using minoxidil and finasteride for hair loss, and there are discussions about various shampoos and treatments for dandruff.
The conversation is about a user's hair loss treatment routine, which includes RU58841 for 9 months and Dutasteride for 6 months, with other unspecified treatments considered extra. One user inquired about the source of RU58841.
Female using Rogaine foam for hair loss had scalp punch biopsy, diagnosed with Androgenetic Alopecia (AGA). Doctor recommended starting Spironolactone 50mg.
The conversation is about a 23-year-old who started treating their hair loss with daily oral dutasteride (0.5mg), oral minoxidil (2.5mg), topical RU58841 (80mg), and weekly microneedling at 1.5mm after seeing others' success stories. Significant improvements have been noted, and there is optimism for even better results in the next 6 months.
Comparing the effectiveness of RU58841, Pyrilutamide and CB-03-01 as treatments for hair loss, with people discussing different aspects such as binding affinity, time of inhibition, safety data and cost.
Treating hair loss with a combination of topical minoxidil and finasteride, as well as keto shampoo twice weekly; other treatments such as microneedling and oral finasteride were discussed but the user is hesitant due to potential scarring. Additionally, another user suggested switching to oral minoxidil for further gains.
Finasteride can reduce DHT in the genitalia, potentially causing side effects like reduced erections and penile fibrosis. Using PDE5 inhibitors like Tadalafil or Sildenafil may help maintain penile health and prevent fibrosis.
After 4 months on oral minoxidil with no significant hair regrowth, a user is frustrated and considering alternative treatments since they can't take finasteride due to side effects. Suggestions include natural DHT blockers, lifestyle changes, and other hair care tips.
The effects of finasteride and dutasteride on beard growth, whether minoxidil would help with facial hair loss caused by DHT blockers, and anecdotal evidence from users who have experienced either decreased or increased facial hair density while using these treatments.
The conversation is about skepticism towards the hair loss treatments RU58841 and Pyrilutamide, with users discussing the lack of human testing for RU58841 and the ongoing trials for Pyrilutamide. Some users believe RU58841 has more anecdotal success, while others highlight Pyrilutamide's current research progress.
Stopping treatments like Minoxidil, Finasteride, or Dutasteride leads to hair loss reversal. Personal reasons, such as planning for a baby, can influence the decision to stop these treatments despite the known consequences.